Health and Healthcare
Blast Off For Peregrine Pharma on Lung Cancer Update
Published:
Last Updated:
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is surging on news updating its non-small cell lung cancer trial. The company said that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC).
The blinded study evaluated two dose levels of bavituximab given with docetaxel versus docetaxel plus placebo (control arm). Today’s rep[ort on the interim data showed a statistically significant improvement in overall survival and a doubling of median overall survival in the bavituximab-containing arms compared to the control arm.
Joseph Shan, vice president of clinical and regulatory affairs at Peregrine said, “The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013.”
Peregrine shares are now up a monster 49% at $4.59 on more than 7 million shares as of 1:22 PM EST and the market capitalization rate here is a mere $355 million.
JON C. OGG
Is Your Money Earning the Best Possible Rate? (Sponsor)
Let’s face it: If your money is just sitting in a checking account, you’re losing value every single day. With most checking accounts offering little to no interest, the cash you worked so hard to save is gradually being eroded by inflation.
However, by moving that money into a high-yield savings account, you can put your cash to work, growing steadily with little to no effort on your part. In just a few clicks, you can set up a high-yield savings account and start earning interest immediately.
There are plenty of reputable banks and online platforms that offer competitive rates, and many of them come with zero fees and no minimum balance requirements. Click here to see if you’re earning the best possible rate on your money!
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
